REMARKS

In the Office Action dated January 17, 2007, claims 1-18 were subjected to a restriction/election requirement by the Examiner.

In response, applicant has elected to prosecute the compound 2-methylene-19-nor-20(S)-1α,25-dihydroxy vitamin D3 (referred to in the specification as 2MD), and its use in treating the disease of ulcerative colitis. Accordingly, claims 1-2, 4-7, 9-10 and 12-17 read on the elected compound and disease.

Examination on the merits of the claims is requested.

Respectfully submitted,

ANDRUS, SCEALES, STARKE & SAWALL, LLP



Thomas M. Wozny
Reg. No. 28,922

Andrus, Sceales, Starke & Sawall, LLP
100 East Wisconsin Avenue, Suite 1100
Milwaukee, WI 53202
(414) 271-7590